Literature DB >> 36153376

Dual-energy CT with virtual monoenergetic images and iodine maps improves tumor conspicuity in patients with pancreatic ductal adenocarcinoma.

Hongwei Liang1, Yang Zhou1, Qiao Zheng1, Gaowu Yan2, Hongfan Liao1, Silin Du1, Xiaohui Zhang1, Fajin Lv1, Zhiwei Zhang3, Yong-Mei Li4.   

Abstract

OBJECTIVES: To evaluate the value of monoenergetic images (MEI [+]) and iodine maps in dual-source dual-energy computed tomography (DECT) for assessing pancreatic ductal adenocarcinoma (PDAC), including the visually isoattenuating PDAC.
MATERIALS AND METHODS: This retrospective study included 75 PDAC patients, who underwent contrast-enhanced DECT examinations. Conventional polyenergetic image (PEI) and 40-80 keV MEI (+) (10-keV increments) were reconstructed. The tumor contrast, contrast-to-noise ratio (CNR) of the tumor and peripancreatic vessels, the signal-to-noise ratio (SNR) of the pancreas and tumor, and the tumor diameters were quantified. On iodine maps, the normalized iodine concentration (NIC) in the tumor and parenchyma was compared. For subjective analysis, two radiologists independently evaluated images on a 5-point scale.
RESULTS: All the quantitative parameters were maximized at 40-keV MEI (+) and decreased gradually with increasing energy. The tumor contrast, SNR of pancreas and CNRs in 40-60 keV MEI (+) were significantly higher than those in PEI (p < 0.05). For visually isoattenuating PDAC, 40-50 keV MEI (+) provided significantly higher tumor CNR compared to PEI (p < 0.05). The reproducibility in tumor measurements was highest in 40-keV MEI (+) between the two radiologists. The tumor and parenchyma NIC were 1.28 ± 0.65 and 3.38 ± 0.72 mg/mL, respectively (p < 0.001). 40-50 keV MEI (+) provided the highest subjective scores, compared to PEI (p < 0.001).
CONCLUSIONS: Low-keV MEI (+) of DECT substantially improves the subjective and objective image quality and consistency of tumor measurements in patients with PDAC. Combining the low-keV MEI (+) and iodine maps may yield diagnostically adequate tumor conspicuity in visually isoattenuating PDAC.
© 2022. The Author(s).

Entities:  

Keywords:  Dual-energy computed tomography; Iodine maps; Pancreatic cancer; Tumor conspicuity; Virtual monoenergetic images

Year:  2022        PMID: 36153376      PMCID: PMC9509509          DOI: 10.1186/s13244-022-01297-2

Source DB:  PubMed          Journal:  Insights Imaging        ISSN: 1869-4101


  26 in total

1.  Virtual monochromatic image at lower energy level for assessing pancreatic ductal adenocarcinoma in fast kV-switching dual-energy CT.

Authors:  Y Noda; S Goshima; T Kaga; T Ando; T Miyoshi; N Kawai; H Kawada; Y Tanahashi; M Matsuo
Journal:  Clin Radiol       Date:  2019-12-23       Impact factor: 2.350

2.  Assessment of an advanced image-based technique to calculate virtual monoenergetic computed tomographic images from a dual-energy examination to improve contrast-to-noise ratio in examinations using iodinated contrast media.

Authors:  Katharine L Grant; Thomas G Flohr; Bernhard Krauss; Martin Sedlmair; Christoph Thomas; Bernhard Schmidt
Journal:  Invest Radiol       Date:  2014-09       Impact factor: 6.016

3.  Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results.

Authors:  Miriam Klauss; Max Schöbinger; Ivo Wolf; Jens Werner; Hans-Peter Meinzer; Hans-Ulrich Kauczor; Lars Grenacher
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

4.  Multireader evaluation of lesion conspicuity in small pancreatic adenocarcinomas: complimentary value of iodine material density and low keV simulated monoenergetic images using multiphasic rapid kVp-switching dual energy CT.

Authors:  Michelle M McNamara; Mark D Little; Lauren F Alexander; L Van Carroll; T Mark Beasley; Desiree E Morgan
Journal:  Abdom Imaging       Date:  2015-06

5.  Dual-energy MDCT in hypervascular liver tumors: effect of body size on selection of the optimal monochromatic energy level.

Authors:  Achille Mileto; Rendon C Nelson; Ehsan Samei; Kingshuk Roy Choudhury; Tracy A Jaffe; Joshua M Wilson; Daniele Marin
Journal:  AJR Am J Roentgenol       Date:  2014-12       Impact factor: 3.959

6.  Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations.

Authors:  Jin Hee Kim; Seong Ho Park; Eun Sil Yu; Myung-Hwan Kim; Jihun Kim; Jae Ho Byun; Seung Soo Lee; Hye Jeon Hwang; Jae-Yeon Hwang; Sang Soo Lee; Moon-Gyu Lee
Journal:  Radiology       Date:  2010-08-09       Impact factor: 11.105

7.  Dual-energy CT in early acute pancreatitis: improved detection using iodine quantification.

Authors:  Simon S Martin; Franziska Trapp; Julian L Wichmann; Moritz H Albrecht; Lukas Lenga; James Durden; Christian Booz; Thomas J Vogl; Tommaso D'Angelo
Journal:  Eur Radiol       Date:  2018-11-28       Impact factor: 5.315

8.  Diagnostic value of the delayed phase image for iso-attenuating pancreatic carcinomas in the pancreatic parenchymal phase on multidetector computed tomography.

Authors:  Kousei Ishigami; Kengo Yoshimitsu; Hiroyuki Irie; Tsuyoshi Tajima; Yoshiki Asayama; Akihiro Nishie; Masakazu Hirakawa; Yasuhiro Ushijima; Daisuke Okamoto; Shigenori Nagata; Yunosuke Nishihara; Koji Yamaguchi; Akinobu Taketomi; Hiroshi Honda
Journal:  Eur J Radiol       Date:  2007-10-24       Impact factor: 3.528

9.  Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.

Authors:  C G Moertel; S Frytak; R G Hahn; M J O'Connell; R J Reitemeier; J Rubin; A J Schutt; L H Weiland; D S Childs; M A Holbrook; P T Lavin; E Livstone; H Spiro; A Knowlton; M Kalser; J Barkin; H Lessner; R Mann-Kaplan; K Ramming; H O Douglas; P Thomas; H Nave; J Bateman; J Lokich; J Brooks; J Chaffey; J M Corson; N Zamcheck; J W Novak
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

10.  Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment.

Authors:  Jan Baxa; Tana Matouskova; Gabriela Krakorova; Bernhard Schmidt; Thomas Flohr; Martin Sedlmair; Jiri Bejcek; Jiri Ferda
Journal:  Eur Radiol       Date:  2015-11-12       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.